Insmed’s first product is approved and launches in Japan. Insmed reports positive Phase 1 data for its earlier-stage product candidate in healthy volunteers.
2021
2020
Insmed’s first product is approved in Europe; initial country launches begin
2020
Insmed reports positive data for its Phase 2 product candidate and announces plans to advance to Phase 3 development.
2019
Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth.
2018
Insmed is granted accelerated approval by the FDA for its first therapy.
2018
Insmed submits a New Drug Application to the FDA for its lead product candidate.
